97306 ⎘
Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Neutralizing anti-TL1A monoclonal antibodies
#302Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
#303Method of treating allergic asthma with antibodies to IL-6
#304Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage
#305Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
#306Multivalent and multiepitopic antibodies having agonistic activity and methods of use
#307TUMOR NECROSIS FACTOR-LIKE LIGAND 1A SPECIFIC ANTIBODIES AND COMPOSITIONS AND USES THEREOF
#308Antagonists of IL-6 to raise albumin and/or lower CRP
#309METHODS FOR ADMINISTERING ANTI-IL-5 ANTIBODIES
#310Anti-Zika virus antibodies and methods of use
#311Methods of treating psoriatic arthritis using IL-17 antagonists
#312Human Anti-Tau Antibodies
#313Antibody-urease conjugates for therapeutic purposes
#314Antibodies against BACE1 and use thereof for neural disease immunotherapy
#315Anti-coagulation factor XI antibodies
#316Anti-GPIIB/IIIA antibodies and uses thereof
#317Bispecific antibodies against CD3 and CD20
#318Antibody binding to carbonic anhydrase and use thereof
#319PROTEIN PURIFICATION USING DISPLACEMENT CHROMATOGRAPHY
#320Methods for reducing the viscosity of liquid pharmaceutical formulations comprising therapeutic proteins
#321Synergistic combinations of OX40L antibodies for the treatment of GvHD
#322Heterodimeric antibodies that bind CD3 and PSMA
#323Method of treating inflammation by administering antibody molecules which bind IL-17A and IL-17F
#324Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
#325Anti-serum albumin binding variants
#326Multivalent and monovalent multispecific complexes and their uses
#327Antibody-drug conjugate having cyclic benzylidene acetal linker
#328Antibodies to TIGIT
#329Synergistic combinations of OX40L antibodies for the treatment of GvHD
#330Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
#331Antibodies specific for MMP9
#332Combination therapies with anti CD40 antibodies
#333Velocity factor
#334ANTI-SIGLEC-8 ANTIBODIES AND METHODS OF USE THEREOF
#335Anti-factor D antibodies and conjugates
#336Antibodies Against Tissue Factor Pathway Inhibitor
#337Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis
#338Anti-tigit antibodies and methods of use
#339Anti-IL-17 antibodies
#340Engineered antibody-interferon mutant fusion molecules
#341Recombinant IgG4 monovalent antibodies
#342Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
#343Conjugates of cysteine engineered antibodies
#344Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
#345Anti-CLL-1 antibodies and methods of use
#346Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
#347Factor IX polypeptides and methods of use thereof
#348Humanized or chimeric CD3 antibodies
#349Antibodies specific for enteroviruses that infect humans
#350Compositions and methods for inhibiting PDGFRbeta and VEGF-A
#351Engineered immunoglobulin Fc polypeptides displaying improved complement activation
#352Fabs-in-tandem immunoglobulin and uses thereof
#353Fabs-in-tandem immunoglobulin and uses thereof
#354Factor IX polypeptides and methods of use thereof
#355Antibody therapeutics that bind CD47
#356Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
#357THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR INDUCING TROGOCYTOSIS
#358Factor IX polypeptides and methods of use thereof
#359IL-8 antibodies
#360Antibody which specifically reacts with human integrin A6B4
#361Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
#362Compositions and methods for antibodies targeting BMP6
#363Humanized or chimeric CD3 antibodies
#364Factor IX polypeptides and methods of use thereof
#365Antibody constant region variant
#366Methods of inhibiting growth of a colon cancer tumor in a subject by administering monoclonal antibodies to G protein-coupled receptor 49 (GPR49)
#367Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
#368CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC PAYLOAD
#369METHODS FOR TREATING PSORIASIS USING AN ANTI-IL-23 ANTIBODY
#370Antibody molecules to dengue virus and uses thereof
#371Novel Immunotherapy Libraries
#372Proteins specific for BAFF and B7RP1 and uses thereof
#373Fusion immunomodulatory proteins and methods for making same
#374Therapy involving antibodies against Claudin 18.2 for treatment of cancer
#375Methods for treating hypophosphatemic disorders
#376ANTIGEN-BINDING MOLECULE FOR ELIMINATING AGGREGATED ANTIGENS
#377Liquid Antibody Formulation With Improved Aggregation Properties
#378Inert format
#379Antibodies to TNFα
#380Protein purification using displacement chromatography
#381Methods of treating an IL-17A mediated pathological condition
#382Anti-FOLR1 Immunoconjugate Dosing Regimens
#383VEGF neutralizing prodrugs for the treatment of ocular conditions
#384Method of improving patient survivability and quality of life by administering an anti-IL-6 antibody
#385Anti-IL-6 antibody for use in the treatment of cachexia
#386Human anti-tau antibodies
#387Antibody molecules to dengue virus and uses thereof
#388Anti-Siglec-8 antibodies and methods of use thereof
#389Monoclonal antibody against human midkine
#390Fc variants with altered binding to FcRn
#391Dimeric protein with triple mutations
#392Deimmunized serum-binding domains and their use in extending serum half-life
#393Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
#394Methods of treating tumors with engineered antibody-interferon mutant fusion molecules
#395Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
#396Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
#397Binding molecules with antitumoral activity
#398Methods of inhibiting solid tumor growth by administering GPR49 antibodies
#399Anti-ADDL monoclonal antibody and uses thereof
#400Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
#401Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor
#402Administration of alpha4beta7 hetero-dimer-specific antibody
#403Production of heterodimeric proteins
#404Optimized anti-CD3 variable regions
#405Protein purification using displacement chromatography
#406Velocity factor
#407Antibody variants and uses thereof
#408Modified variable domain molecules and methods for producing them
#409Anti-IL-23 antibodies
#410IP-10 antibody dosage escalation regimens
#411Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration
#412Antibodies that specifically bind alpha toxin and methods of use
#413Assay for benzylpiperazine and metabolites
#414Modified antibody with improved half-life
#415Methods of treating ankylosing spondylitis using IL-17 antagonists
#416Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
#417Anti-serum albumin binding variants
#418Factor IX polypeptides and methods of use thereof
#419Immunobinders directed against sclerostin
#420Humanized antibodies to iNKT
#421TRAIL R2-specific multimeric scaffolds
#422Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
#423STABILIZED ANTIBODY PREPARATIONS AND USES THEREOF
#424Anti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity
#425Methods of making and using multispecific antibody panels and antibody analog panels
#426Antibody humanization by framework assembly
#427Hepatitis B virus specific antibody and uses thereof
#428ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRP
#429Antagonists of IL-6 to prevent or treat thrombosis
#430Covalent disulfide-linked diabodies and uses thereof
#431Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
#432High concentration anti-TNFα antibody liquid formulations
#433CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#434AX1 PCSK9 antagonists
#435Treatment of stroke comprising anti-MAG antibodies
#436Multifunctional antibody conjugates
#437Velocity factor
#438POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS
#439ANTAGONISTS, USES & METHODS FOR PARTIALLY INHIBITING TNFR1
#440Anti-ferroportin 1 monoclonal antibodies and uses thereof
#441Fc variants with altered binding to FcRn
#442Human anti-tau antibodies
#443Antibody constant region variant
#444MODIFIED SINGLE DOMAIN ANTIGEN BINDING MOLECULES AND USES THEREOF
#445Antibodies against tissue factor pathway inhibitor
#446SPECIFIC BINDING PROTEINS AND USES THEREOF
#447Anti-serum albumin binding variants
#448ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS
#449Production of heteromultimeric proteins
#450J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
#451POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS
#452PEPTIDES CAPABLE OF BINDING TO SERUM PROTEINS AND COMPOUNDS, CONSTRUCTS AND POLYPEPTIDES COMPRISING THE SAME
#453Compositions and methods for inhibiting PDGFRβ and VEGF-A
#454METHODS FOR SYSTEMATIC CONTROL OF PROTEIN STABILITY
#455IMMUNOTHERAPY COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF AMYLOIDOSIS
#456ANTI-FERROPORTIN 1 MONOCLONAL ANTIBODIES AND USES THEREOF
#457Fc variants with altered binding to FcRn
#458Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
#459POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTSMETHODS FOR
#460REAGENTS FOR INDUCING AN IMMUNE RESPONSE
#461Recombinant IgG4 monovalent antibodies
#462Antibodies to TNFα
#463Polypeptides, antibody variable domains and antagonists
#464Antibody molecules which bind IL-17A and IL-17F
#465Polypeptides, antibody variable domains and antagonists methods for
#466POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS
#467Engineered anti-alpha V-integrin hybrid antibodies
#468METHODS FOR SELECTING PROTEASE RESISTANT POLYPEPTIDES
#469POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS
#470FC VARIANTS WITH ALTERED BINDING TO FCRN
#471Fc variants with altered binding to FcRn
#472Fc variants with altered binding to FcRn
#473Fc variants with altered binding to FcRn
#474FC variants with altered binding to FCRN
#475Fc variants with altered binding to FcRn
#476CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#477METHODS FOR ADMINISTERING ANTI-IL-5 ANTIBODIES
#478METHODS FOR ADMINISTERING ANTI-IL-5 ANTIBODIES
#479Fc variants with altered binding to FcRn
#480POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS
#481Stabilized High Concentration Anti-Integrin alphavbeta3 Antibody Formulations
#482Fc variants with altered binding to FcRn